



If you would like to share news or information with our readers, please send the unique stories, business

news organization events, and school news to us including your name and phone number in case more information is needed.

For news and information consideration, please send to News@scdaily.com or contact

**John Robbins** 281-965-6390  
**Jun Gai** 281-498-4310

**Publisher:** Wea H. Lee  
**President:** Catherine Lee  
**Editor:** John Robbins

**Address:** 11122 Bellaire Blvd., Houston, TX 77072  
**E-mail:** News@scdaily.com



Inside C2

# Southern DAILY

Make Today Different

Southern Daily News is published by Southern News Group Daily

Wednesday, September 07 2022

## UK weighs huge support package as Europe battles energy crisis

HELSINKI/ZURICH, Sept 6 (Reuters) - - Britain's new prime minister was working on what looks set to be Europe's biggest energy crisis support package so far as countries scramble to protect households and businesses from soaring bills and shore up struggling suppliers.

Liz Truss, who took over from Boris Johnson on Tuesday, is planning to freeze household energy bills at the current level for this winter and next, paid for by government-backed loans to suppliers, the BBC reported, adding the scheme could cost 100-130 billion pounds (\$116-151 billion).

The government is also working on help for businesses, but this is likely to be more complex and would be reviewed more frequently, the BBC said.

European governments are pushing through multibillion-euro packages to prevent utilities from collapsing and protect households amid soaring energy costs triggered mainly by the fallout from Russia's invasion of Ukraine.

Benchmark European gas prices have surged about 340% in a year, and jumped as much as 35% on Monday after Russia's state-controlled Gazprom (GAZP.MM) said it would indefinitely extend a shutdown to the major Nord Stream 1 gas pipeline. [read more](#)

Europe has accused Russia of weaponising energy supplies in retaliation for Western sanctions imposed on Moscow over its invasion of Ukraine. Russia blames those sanctions for causing the gas supply problems, which it puts down to pipeline faults.

Germany said on Sunday it would spend at least 65 billion euros on shielding customers and businesses from rocketing inflation, triggered mainly by higher energy costs. [read more](#)

Several countries are also providing billions in support to energy distributors exposed to wild swings in prices that are forcing them to cough up huge collateral for supplies.

Norwegian energy company Equinor has estimated these collateral payments, known as margin calls, amounted to at least 1.5 trillion euros (\$1.5 trillion) in Europe, excluding Britain. [read more](#)

### RECESSION FEARS

Finnish utility Fortum (FORTUM.HE) said on Tuesday it had signed a bridge financing arrangement with government investment company Solidium worth 2.35 billion euros to cover its collateral needs. [read more](#)

A Finnish government official told Reuters the support was in addition to the 10 billion euros of liquidity guarantees Helsinki announced for power companies on Sunday. [read more](#)

"The ongoing energy crisis in Europe is caused by Russia's decision to use energy as a weapon, and it is now also severely affecting Fortum and other Nordic power producers," Fortum Chief Executive Markus Rauramo said in a statement.

Swiss utility Axpo (AXPOH.UL) said it had sought and received a credit line of up to 4 billion Swiss francs (\$4.1 billion) from the government to help its finances. [read more](#)



## Updated COVID vaccines to be ready this week, U.S. eyes annual shots

WASHINGTON, Sept 6 (Reuters) - New COVID-19 boosters aimed at fighting currently circulating variants of the coronavirus will be widely available this week, U.S. health officials said on Tuesday, adding that the vaccine is moving closer to an annual jab, as with flu shots.

By the end of this week, 90% of Americans will live within five miles (8 km) of sites carrying updated vaccines, U.S. health secretary Xavier Becerra said at a White House briefing.

They will remain available at no cost, White House COVID-19 Response Coordinator Ashish Jha told reporters.

Officials said people could get the new boosters this fall and winter alongside their regular annual flu shots.

The redesigned boosters, green-lighted by U.S. health regulatory agencies last week, aim to tackle the BA.5 and BA.4 sub-lineages of the virus's Omicron variant. [read more](#)

The so-called bivalent vaccines also still target the original version of the virus.

With Ledger Academy's Free Lessons, Learn the Right Reflexes during a Bear Market ! Increase your Crypto Knowledge and Understand why the Market is Changing. Free Access to our "For the last two years, this virus has continued evolving while our vaccines have stayed the same, but now we have a vaccine that matches the dominant strain out there," he said. "For the first time since December of 2020, these vaccines are vaccines that have caught up with the virus."

U.S. Centers for Disease Control and Prevention (CDC) Director Rochelle Walensky said even with the seven-day average of COVID hospitalizations down 14% to 4,500 per day, annual shots could save thousands of lives.

"Modeling projections show that an uptake of updated COVID-19 vaccine doses similar to an annual flu vaccine coverage early this fall could prevent as many as 100,000 hospitalizations and 9,000 deaths, and save billions of dollars in direct medical costs," she said.

Omicron subvariants BA.5 and BA.4, which are targeted by the retooled boosters, account for over 88% and 11% of circulating viruses, respectively, she said.

敬請關注我們的新媒體帳號  
Follow us on social media



Southern News  
美南新聞



美南微信  
公眾號



今日頭條  
美國美南網



抖音  
美國美南網



西瓜视频  
美國美南網



Facebook Page  
Southern News  
美南新聞



Tik Tok ID:  
Southern News Group



Instagram ID:  
Southern News

# WEA LEE'S GLOBAL NOTES

09/05/2022

## Mill Fire Burns Homes In California

The Mill fire which sparked north of the City of Weed in California has burned more than four thousand acres and as many as 100 homes may have been destroyed.

Three people have been injured in the blaze. 132 other structures have been affected nearby.

Officials said Mill the fire began in a shed in an inside portion of forest products. In the meantime, a forest fire

crew also arrived to combat the nearby mountain fire where more than 1,000 residents were forced to leave the area.

Governor Newsom declared a state emergency to increase available resources for the firefighters and local people.

This is very sad to say, but because of the changing weather and the very dry season, California suffers many mountain fires.



Asian American politician, Andrew Yang, along with a group of Republican and Democratic officials, are forming a new third party called, "Forward."

Yang told reporters that 62% of Americans now want a third party, a record high, because they can see that our leaders aren't getting the job done.

The new party is planning a national convention next

summer and will soon seek to run in the 2024 presidential election.

We sincerely admire Andrew Yang's ambition. He is really the light of our people. We deeply feel that today in a very difficult political environment, we must have a voice to the politicians and get their attention and express our dissatisfaction and unite in our strength.



**Wea H. Lee**  
Wealee@scdaily.com

Chairman of International District Houston Texas  
Publisher Southern Daily Wea H. Lee

Southern News Group Chairman / CEO  
Chairman of International Trade & Culture Center  
Republic of Guiana Honorary consul at Houston Texas

## Andrew Yang Working On A Third Party



Media and social media contact information including logos for iTalkBB, STV LIVE, Southern News, WeChat, 头条, 抖音, 西瓜视频, Facebook Page: Southern News, TikTok ID: Southern News Group, and Instagram ID: Southern News.

**Southern DAILY** Make Today Different

## Editor's Choice



Palestinians inspect the house of Tel Aviv attacker Raed Hazem after it was demolished by Israeli forces in Jenin in the Israeli-occupied West Bank. REUTERS/Raneen Sawafta



Queen Elizabeth welcomes Liz Truss during an audience where she invited the newly elected leader of the Conservative party to become Prime Minister and form a new government, at Balmoral Castle, Scotland, Britain. Jane Barlow/Pool



Boris Johnson leaves Downing Street, on his last day in office as British prime minister, watched by his wife Carrie, in London. REUTERS/Kevin Coombs



A view shows a burning house as the Fairview Fire near Hemet, California. REUTERS/David Swanson



People pull a car through a water-logged road following torrential rains in Bengaluru, India. REUTERS/Stringer



Director Olivia Wilde attends the 79th Venice Film Festival. REUTERS/Guglielmo Mangiapane

Southern DAILY Make Today Different

BUSINESS

A Texas Research Team Has Developed A COVID-19 Vaccine That Could Be A Global Game Changer



Dr. Peter Hotez and Dr. Maria Elena Bottazzi of Texas Children's Hospital and Baylor College of Medicine have developed a COVID-19 vaccine that could prove beneficial to countries with fewer resources. (Photo/Max Trautner/Texas Children's Hospital)


Compiled And Edited By John T. Robbins, Southern Daily Editor

A vaccine authorized in December for use in India may help solve one of the most vexing problems in global public health: How to supply lower-income countries with a COVID-19 vaccine that is safe, effective and affordable. The vaccine is called CORBEVAX. It uses old but proven vaccine technology and can be manufactured far more easily than most, if not all, of the COVID-19 vaccines in use today. "CORBEVAX is a game changer," says Dr. Keith Martin, executive director of the Consortium of Universities for Global Health in Washington, D.C. "It's going to enable countries around the world, particularly low-income countries, to be able to produce these vaccines and distribute them in a way that's going to be affordable, effective and safe." The story of CORBEVAX begins some two decades ago. Peter Hotez and Maria Elena Bottazzi were medical researchers at George Washington University in Washington, D.C., where they worked on vaccines and treatments for what are called neglected tropical diseases, such as schistosomiasis and hookworm. When a strain of coronavirus known as SARS broke out in 2003, they decided to tackle that disease. After moving to Houston to affiliate with Baylor College of Medicine and the Texas Children's

Center for Vaccine Development, they created a vaccine candidate using protein subunit technology. This involves using proteins from a virus or bacterium that can induce an immune response but not cause disease. "It's the same technology as the hepatitis B vaccine that's been around for decades," Hotez says. Their SARS vaccine candidate looked promising, but then the SARS outbreak petered out. No evidence of disease, no need for a vaccine. When a new strain of coronavirus triggered the COVID-19 pandemic, Hotez and Bottazzi figured they could dust off their old technology and modify it for use against COVID-19. After all, the virus causing COVID-19 and the virus causing SARS are quite similar. Hotez says they tried to interest government officials in the vaccine, but they weren't impressed. "People were so fixated on innovation that nobody thought, 'Hey, maybe we could use a low-cost, durable, easy-breezy vaccine that can vaccinate the whole world,'" Hotez says. "We really honestly couldn't get any traction in the U.S., but our mission is always to enable technologies for low- and middle-income countries production and use," Bottazzi recalls.

So they turned to private philanthropies. A major donor early on was the JPB Foundation in New York. "The rest were all Texas philanthropies: the Kleberg Foundation, the [John S.] Dunn Foundation, Tito's Vodka," Hotez says. The MD Anderson Foundation also chipped in. "When people say, 'Why did we move [from Washington, D.C.] to Texas?' Well, we knew that this was a great philanthropic environment. So this is really very much a Texas vaccine," although there were other, smaller donors from all over the country.

Hotez says that unlike the mRNA vaccines from Pfizer and Moderna, and the viral vector vaccine from Johnson & Johnson, protein subunit vaccines like CORBEVAX have a track record. So he and Bottazzi were relatively certain CORBEVAX would be safe and effective. "And it's cheap, a dollar, dollar fifty a dose," Hotez says. "You're not going to get less expensive than that."



Clinical trials showed they were right to be confident CORBEVAX would work. An unpublished study conducted in India involving 3,000 volunteers found the vaccine to be 90% effective in preventing disease caused by the original COVID-19 virus strain and 80% against the delta variant. It's still being tested against omicron. But CORBEVAX is already entering the real world. Last month, the vaccine received emergency use authorization from regulators in India. An Indian vaccine manufacturer called Biological E Ltd is now making the vaccine. The company says it is producing 100 million doses per month and has already sold 300 million doses to the Indian government. "The real beauty of the CORBEVAX vaccine that Drs. Hotez and Bottazzi created is that intellectual property of this vaccine will be available to everybody," Keith Martin says. "So you can get manufacturers in Senegal, and South Africa and Latin America to be able to produce this particular vaccine." By contrast, the makers of Pfizer and Moderna, for example, are not sharing their recipe. One drawback to the CORBEVAX technology is that it can't be modified as quickly as mRNA vaccines can to adjust to new variants. That forces public health officials to make difficult choices. "Something which can be adapted the fastest versus something that can be adapted relatively quickly, but then more importantly can be

manufactured at a large global capacity and at a cost of production which is much lower," says Prashant Yadav, senior fellow at the Center for Global Development in Washington, D.C. The thought is some protection may be better than no protection. Of course, the ideal vaccine would have both qualities, and Peter Hotez is at work trying to develop technologies that can do that.



"There's no issue with pushing innovation," he says. "I think that's one of the really positive features of the U.S. vaccination program for COVID. The problem was it wasn't balanced with a portfolio of oldies but goodies." Hotez is hoping his oldie but goodie will usher in a brighter future for the world. (Courtesy npr.org)

Related: Wants To Break Into The U.S. Market For Now The Team Focuses Its Efforts Abroad Where COVID-19 Variants Surface More Quickly



Maria Bottazzi, left, and Peter Hotez at the Tropical Medicine Lab at Texas Children's Hospital Center for Vaccine Development in Houston on Oct. 5, 2021. (Photo/J. Rex/The Texas Tribune)

The day before COVID-19 claimed its first Texas victim in 2020, Dr. Peter Hotez was a guest on the popular Austin-based podcast "The Drive." After 10 years of research into coronavirus vaccines, Hotez and his Houston team needed an infusion of cash to build on their past work and make a vaccine that could, as Hotez told listeners then, "rescue the world" from the deadly emerging coronavirus pandemic. "You'd think that people would be pretty eager to support us to move this forward, but so far it hasn't happened," the Houston pediatrician and vaccine scientist told the host, Dr. Peter Attia, on March 14, 2020. By the following week, major cities in Texas began to shut down to avoid widespread community outbreaks. But Hotez's plea worked. The donations started coming in support of efforts in the deadly new pandemic at the Baylor College of Medicine at the Texas Children's Hospital Center for Vaccine Development, co-directed

by Hotez and Dr. Maria Elena Bottazzi in Houston — both of whom are celebrated pioneers in the area of vaccines for neglected tropical diseases like chagas and schistosomiasis.



Maria Bottazzi replaces vials of the RBD-based SARS-CoV-2 vaccine into a freezer at the Tropical Medicine Lab at Texas Children's Hospital Center for Vaccine Development in Houston on Oct. 5, 2021. (Photo/J. Rex/The Texas Tribune)

Among the gifts was a \$1 million infusion of cash in May 2020 by the philanthropic arm of Texas-based Tito's Handmade Vodka, whose director of global impact and research, Sarah Everett, was tuned in when Hotez asked for help in reviving their research. "We decided that somebody should help restart that work immediately," Everett said. Now, nearly 18 months later, the Houston team's vaccine, called Corbevax by its maker in India, is cheap, has no patent, can be made by many vaccine producers globally — including those in low- and middle-income countries — and is poised to receive approval for widespread global use. The Indian government has promised the pharmaceutical company Biological E Limited, which is making the vaccine in that country, that it will buy 300 million doses with the potential for more. A halal version of the vaccine, for use in Islamic countries because it doesn't contain animal-based ingredients, is also about to start clinical trials in Indonesia. And later this year, the company hopes the vaccine will be endorsed by the World Health Organization for use globally, which could open the doors to quicker authorization in several countries that need it. But here in the United States, this "truly Texas vaccine," as its creators like to call it, has no home. A Texas-style vaccine The fact that the vaccine even exists can be traced to a lot of Texas money, including funds from The Robert J. Kleberg, Jr. and Helen C. Kleberg Foundation and the M.D. Anderson Foundation. Several high-level and anonymous individual donors pitched in, as well as the JPB Foundation in New York. Those donations funded a vaccine prototype with the initial doses mixed in the Houston lab and transferred to Biological E in India in May 2020. By November, BioE began clinical trials of the vaccine in India, where the delta variant was first identified and which has one of the lowest vaccination rates in the world. Total cost from creation to market was between \$5 million and \$7 million, Bottazzi said. (Article Continues Below)

Southern DAILY Make Today Different

COMMUNITY

(Article Continues From Above)

A Texas Research Team Has Developed A COVID-19 Vaccine That Could Be A Global Game Changer

Compiled And Edited By John T. Robbins, Southern Daily Editor



The U.S. government has yet to get on board. Operation Warp Speed, the public-private partnership created by the federal government to accelerate treatments and vaccines for COVID-19, spent none of its billions at the Houston lab. Most experts, including Hotez and Bottazzi, agree that's because most of the funding and the attention — and the bets — are on the vaccines made earliest in the pandemic, and with the newest technology, by Pfizer, Moderna and Johnson & Johnson and a few others. "We're pushing the new ways because they're better and faster," said Dr. Benjamin Neuman, a Texas A&M University virologist who has been doing coronavirus research since 1996, though he was not involved in any of the approved vaccines' development. "Why wouldn't you want to have it all?"



Left: Maria Bottazzi holds a vial of the RBD-based SARS-CoV-2 vaccine at the Tropical Medicine Lab at Texas Children's Hospital Center for Vaccine Development in Houston on Oct. 5, 2021. Right: A lab worker works on a project at the Texas Children's Hospital Center. (Photo/J. Rex/The Texas Tribune)

protein. Five years ago, Neuman said, that process hadn't been made effective yet. But by the time Hotez was making his plea on Attia's podcast, Moderna was already starting up clinical trials of its mRNA vaccine in partnership with the National Institutes of Health, the biomedical research arm of the U.S. government and the largest center of its kind in the world. And by late 2020, when BioE was rolling out its phase 1 clinical trials with Corbevax in India, Pfizer was already getting emergency use authorization from the U.S. Food and Drug Administration. The Bottazzi and Hotez vaccine relies on a production process very similar to the way the Hepatitis B vaccine is made that's been produced and used around the world for decades. The two argue that the familiarity with the process and the ease with which the materials can be gotten makes it easier to quickly ramp up global production compared to the newer vaccines, even if they came onto the market a little later. But aside from a handful of philanthropies who can see the value of the domino effect — more vaccinations outside this country help lower infections around the world and here — Hotez and Bottazzi have heard nothing about producing or distributing here at home. "Why weren't conventional vaccine technologies given the opportunity of being at the same table as all these other technologies?" Bottazzi said. The answer, Neuman says, is that while conventional technologies — or what he jokingly derided as "the obvious answer" — have a role in global vaccine development, the newer vaccines are stronger than the traditional types that Bottazzi, Hotez and other scientists around the world are developing. Newer vaccines also have a quicker production process than the conventional vaccines, said Neuman, a member of the international committee that named SARS-CoV-2, the virus behind the COVID-19 pandemic.



Peter Hotez at the Tropical Medicine Lab at Texas Children's Hospital Center for Vaccine Development in Houston on Oct. 5, 2021. (Photo/J. Rex/The Texas Tribune)

Development in Houston on Oct. 5, 2021. (Photo/ Justin Rex for The Texas Tribune)

But Neuman agrees that the newer vaccines have distribution challenges: the tangles of intellectual property patents, the availability of materials to produce billions of doses in a short period of time and the logistics of a more complicated transport and storage process. Those challenges can be solved, Neuman said, but until then, the majority of the planet should be vaccinated "by any means necessary," including with conventional vaccines like the one created by Bottazzi and Hotez, if it proves to be safe and effective. "Whatever gets the job done the fastest as long as it's safe for everybody involved," he said. "One plane flight away" While the Houston team waits for a production and distribution partner, the team fields calls every week from other countries asking them for help getting access to the vaccine, Bottazzi said. They ask if they can get the spare doses that Americans are declining or if they can get connected to BioE to export to them from their Indian-made stocks — or if the scientists will share the formula for the prototype. The scientists share the formula with any country or lab who asks for it and help in other ways, however they can. "We're kind of practicing our own version of Texas vaccine diplomacy," Hotez said. Vaccination rates for developing countries are still in the single digits. About 38% of the world population is fully vaccinated against COVID-19. Many African countries, such as Sudan, Kenya and Ethiopia, have a rate below 2%.



The vaccine team at the Tropical Medicine Lab at Texas Children's Hospital Center for Vaccine Development in Houston. (Photo/J. Rex/The Texas Tribune)

that has very little vaccine end up on our shores and set off a new wave of the pandemic," said Dr. James Cutrell, an infectious disease expert at UT Southwestern Medical Center. Right now, the World Health Organization is already monitoring several variants that have been traced to developing countries including Indonesia (21% fully vaccinated), Peru (with one of the highest COVID-19 mortality rates in the world), Colombia, the Dominican Republic and South Africa. "Much of sub-Saharan Africa, large swaths of Latin America and other places like that — they really don't have access to the [mRNA] vaccines," said Cutrell, an associate professor in the department of internal medicine. "That makes it really important and attractive to have some of these cheaper, easier-to-distribute — but hopefully similarly effective — vaccines with more traditional technology, which I think this vaccine and other vaccines like it can contribute."



Dr. Peter Hotez and Dr. Maria Elena Bottazzi of Texas Children's Hospital and Baylor College of Medicine. American problem, international solution As the world scrambles for doses to meet the vaccination demand elsewhere, this nation's vaccination effort has flagged, hitting a wall of hesitation by a significant portion of the American public that is declining the new vaccines, although they have proven to be safe and effective. Hotez and Bottazzi believe their vaccine would likely be more accepted by those who don't trust a vaccine that is unfamiliar to them, like those by Pfizer and Moderna. But from the start, inoculating reticent Americans was never the Houston team's first priority. Bottazzi and Hotez began their work developing coronavirus vaccines as part of their mission at the National School of Tropical Medicine, where Hotez is dean

and Bottazzi is associate dean, to inoculate developing nations against tropical viruses. Fast forward to January 2020, when SARS-CoV-2, the virus that causes COVID-19, was setting off alarms in the U.S. medical community. Bottazzi and Hotez began working to repurpose their coronavirus research program to develop a vaccine against the new virus and distribute it to the same countries they'd focused on throughout their careers. The speed with which the Pfizer and Moderna vaccines were developed and the fact they used newer formulas seemed to spook some Americans and helped fuel politically motivated misinformation campaigns that chipped away at public acceptance. And as this nation's vaccination rate hovers around 57%, it's a matter of debate what is needed to achieve a higher level of immunity as a country. Neuman said he isn't so sure that a more familiar vaccine formula would change a lot of minds in the United States, where the resistance appears to be more political than scientific. "I think that comes from a lot of different places, and I think the main place is sort of, 'You're not the boss of me,'" he said. "Who says you get to tell me what to do?" And I don't think it matters what it is." Even if it would make a difference, the path to emergency use authorization for a COVID-19 vaccine in this country starts with money — for research, for trials, for materials — and ends with firm commitments from the U.S. to support its mass production. The Bottazzi-Hotez shot, at this point, has neither. And so Hotez, who is an internationally known and outspoken warrior against the anti-vaccine movement, and Bottazzi redouble their attention abroad to protect Americans who can't or won't protect themselves. If they can get more of their vaccine overseas within a few months, they can keep the variants from percolating and landing on U.S. soil. "It's a pretty ambitious, audacious goal," Hotez said. "But I think we could get there." (Courtesy texastribune.org)



and Bottazzi is associate dean, to inoculate developing nations against tropical viruses. Fast forward to January 2020, when SARS-CoV-2, the virus that causes COVID-19, was setting off alarms in the U.S. medical community. Bottazzi and Hotez began working to repurpose their coronavirus research program to develop a vaccine against the new virus and distribute it to the same countries they'd focused on throughout their careers.

The speed with which the Pfizer and Moderna vaccines were developed and the fact they used newer formulas seemed to spook some Americans and helped fuel politically motivated misinformation campaigns that chipped away at public acceptance. And as this nation's vaccination rate hovers around 57%, it's a matter of debate what is needed to achieve a higher level of immunity as a country. Neuman said he isn't so sure that a more familiar vaccine formula would change a lot of minds in the United States, where the resistance appears to be more political than scientific. "I think that comes from a lot of different places, and I think the main place is sort of, 'You're not the boss of me,'" he said. "Who says you get to tell me what to do?" And I don't think it matters what it is." Even if it would make a difference, the path to emergency use authorization for a COVID-19 vaccine in this country starts with money — for research, for trials, for materials — and ends with firm commitments from the U.S. to support its mass production. The Bottazzi-Hotez shot, at this point, has neither. And so Hotez, who is an internationally known and outspoken warrior against the anti-vaccine movement, and Bottazzi redouble their attention abroad to protect Americans who can't or won't protect themselves. If they can get more of their vaccine overseas within a few months, they can keep the variants from percolating and landing on U.S. soil. "It's a pretty ambitious, audacious goal," Hotez said. "But I think we could get there." (Courtesy texastribune.org)